Carl J. Pepine, MD, MACCCarl J. Pepine, MD, MACC
Program Chairman

As the Program Chairman, I want to personally invite you to attend the next Vascular Biology Working Group Meeting & Reception, to be held Friday, November 9 in Chicago (the day before AHA begins).

VBWG was founded to unify the broad spectrum of vascular science that is driving the advances related to prevention and management of coronary artery disease. A key function of VBWG is to facilitate a consensus on what implications recent research findings have for present and future patient care.

We host regional meetings throughout the year to provide a forum for the evaluation and integration of vascular biology research for both experienced cardiologists and researchers. We hope you can join us at our next meeting this fall – registration is free; however, seating is limited so we ask that you please register in advance.


The goal of this meeting is to improve the cardiovascular health of patients by providing a forum for the review, exchange and assimilation of findings from vascular biology research for dissemination to the clinical medicine community.

Target Audience

This meeting has been designed for cardiologists, residents/students and researchers.

Educational Objectives

  • To review new data on the pathophysiology of coronary artery disease and its relevance to treatment strategies and outcomes.
  • To understand the pharmacologic and clinical rationale for various treatment options in the CAD patient.
  • To develop a consensus on practical guidelines for day-to-day management of the coronary artery disease patient.

Program Overview

This program is highly relevant and aimed at providing basic to advanced instruction for both experienced cardiologists as well as residents in training. Some of the discussion topics will cover:

  • HFpEF Management
  • Coronary Microvascular Dysfunction
  • Obesity-Related HFpEF
  • Atrial Fibrillation
  • Catheter Ablation vs. Pharmacologic Therapy
  • Cardiovascular Risks
  • Remnant Cholesterol vs. LDL Cholesterol
  • Omega-3 in ASCEND, VITAL and REDUCE-IT Trials
  • Lipids, Liver and Cardiovascular Disease
  • Clinical Trial Data and Management
Meeting organized by
Official Media Partner